Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Dengvaxia Market Size Forecast: How Large Could The Market Become By 2030?
The dengvaxia market has seen rapid expansion in recent years, with projections indicating an increase from $213.36 million in 2025 to $250.81 million in 2026, achieving a compound annual growth rate (CAGR) of 17.6%. Historical growth has been driven by factors such as repeated dengue outbreaks, a significant disease load in tropical areas, vaccination campaigns led by governments, scarce therapeutic alternatives for dengue, and growing public health consciousness.
The market for Dengvaxia is poised for significant expansion over the coming years, with projections indicating it will reach $473.95 million by 2030, driven by a compound annual growth rate (CAGR) of 17.2%. This anticipated growth during the forecast period is fueled by factors such as the broadening of vaccination initiatives, a rising incidence of mosquito proliferation linked to climate change, enhanced public health investments, better infrastructure for vaccine delivery, and a growing need for immunizations associated with travel. Key developments shaping the forecast period involve the scaling up of dengue immunization efforts, an intensified emphasis on preventing endemic diseases, expanding public health awareness campaigns for vaccination, heightened monitoring of illnesses transmitted by mosquitoes, and the reinforcement of vaccination schedules for children and adolescents.
Download A Free Sample Report For Comprehensive Market Insights:
Dengvaxia Market Demand Drivers: What Is Fueling Industry Growth?
The rising occurrence of dengue is anticipated to boost the expansion of the dengvaxia market in the coming period. Dengue is a viral illness spread by Aedes mosquitoes, characterized by symptoms like fever, severe discomfort, and in critical instances, life-threatening conditions such as dengue hemorrhagic fever or dengue shock syndrome. The growing frequency of dengue is driven by factors such as climate shifts, urban expansion, heightened travel activity, and increased breeding sites for mosquitoes, which together result in higher infection rates and a stronger need for preventive and therapeutic options. Dengvaxia serves to prevent dengue by functioning as a potent vaccine that activates the immune system to create a defensive reaction against the dengue virus, thereby lowering the likelihood of infection and severe outcomes while enhancing public health in regions where the disease is endemic. For example, in June 2024, the Centers for Disease Control and Prevention (CDC), a US governmental agency, reported that the Americas recorded more than 9.7 million dengue cases in 2023, which is double the 4.6 million cases from the previous year. Puerto Rico declared a public health emergency after 1,498 cases were identified, and 745 instances were documented among US travelers. Consequently, the elevated prevalence of dengue is fueling growth in the dengvaxia market.
Growing international travel is set to drive the expansion of the dengvaxia market in the future. International travel involves moving between nations for activities like tourism, business, or education. The increase in cross-border movement raises the likelihood of transmitting infectious illnesses, particularly dengue, thereby heightening the demand for preventive actions such as vaccinations. Dengvaxia is utilized in the context of rising international travel to shield travelers from catching dengue in endemic zones and to lower the chance of spreading the disease across national boundaries. As an illustration, in May 2024, the Office for National Statistics, a UK government department, reported that international visits to the UK climbed notably from 31.2 million in 2022 to 38.0 million in 2023. Thus, the surge in international travel is expected to promote growth in the dengvaxia market.
Rising healthcare expenditures are predicted to speed up the growth of the dengvaxia market moving forward. Healthcare expenditures denote the financial funds dedicated by governments, private organizations, or individuals to deliver medical services, treatments, and health-related initiatives. This increase in spending is fueled by a growing need for medical care, progress in health technology, and a higher prevalence of chronic diseases, all of which prompt greater investment in healthcare systems and therapies. In the context of Dengvaxia, healthcare expenditure emphasizes prevention, aiming to cut long-term expenses tied to treating dengue and controlling outbreaks. For example, in May 2024, the Office for National Statistics, a UK government department, indicated that total healthcare spending rose by 5.6% in nominal terms between 2022 and 2023, representing a notable acceleration from the 0.9% growth seen in 2022. Hence, expanding healthcare expenditures will propel the advancement of the dengvaxia market.
Dengvaxia Market Segments: Where Are The Largest Growth Opportunities?
The dengvaxia market covered in this report is segmented –
1) By Type: Dengvaxia, Other Types
2) By Distribution Channel: Hospitals, Clinics, Public Health Programs
3) By Clinical Indication: Prevention In Previously Infected Individuals, Protection In High-Risk Regions, Traveler Immunization, Pediatric And Adolescent Use
Dengvaxia Market Major Participants And Competitive Dynamics
Major companies operating in the dengvaxia market are Sanofi Pasteur Inc.
Access The Complete Dengvaxia Market Report:
Dengvaxia Market Global Footprint: Which Region Holds Market Leadership?
Asia-Pacific was the largest region in the dengvaxia market in 2025. Latin America is expected to be the fastest-growing region in the forecast period. The regions covered in the dengvaxia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model